LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 308 filers reported holding LIGAND PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2020 | $3,430,000 | -58.6% | 34,489 | -60.4% | 0.53% | -66.0% |
Q3 2020 | $8,292,000 | -40.7% | 86,995 | -30.5% | 1.57% | -46.1% |
Q2 2020 | $13,993,000 | +26.8% | 125,101 | -17.6% | 2.92% | +17.9% |
Q1 2020 | $11,038,000 | +90.1% | 151,792 | +172.7% | 2.47% | +158.0% |
Q4 2019 | $5,806,000 | +78.1% | 55,672 | +70.0% | 0.96% | +65.6% |
Q3 2019 | $3,260,000 | -52.3% | 32,748 | -45.3% | 0.58% | -50.1% |
Q2 2019 | $6,831,000 | +12.0% | 59,838 | +23.3% | 1.16% | +8.2% |
Q1 2019 | $6,101,000 | -43.9% | 48,536 | -39.5% | 1.07% | -53.0% |
Q4 2018 | $10,881,000 | +2.8% | 80,183 | +108.0% | 2.28% | +31.7% |
Q3 2018 | $10,584,000 | +2.6% | 38,557 | -22.6% | 1.73% | -0.9% |
Q2 2018 | $10,316,000 | +23.6% | 49,793 | -1.4% | 1.75% | +10.2% |
Q1 2018 | $8,343,000 | +24.8% | 50,514 | +3.4% | 1.58% | +26.0% |
Q4 2017 | $6,687,000 | -36.8% | 48,837 | -37.2% | 1.26% | -40.5% |
Q3 2017 | $10,588,000 | +47.4% | 77,767 | +31.5% | 2.12% | +30.0% |
Q2 2017 | $7,181,000 | – | 59,155 | – | 1.63% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BVF INC/IL | 2,626,160 | $138,136,000 | 24.17% |
KNOTT DAVID M | 1,292,566 | $67,988,972,000 | 13.87% |
GROW Partners, LLC | 200,000 | $10,520,000 | 6.41% |
Opaleye Management Inc. | 90,000 | $4,860,000,000 | 3.82% |
OBERWEIS ASSET MANAGEMENT INC/ | 213,317 | $11,220,000 | 2.72% |
First Light Asset Management, LLC | 60,242 | $3,169,000 | 2.69% |
Timpani Capital Management LLC | 98,956 | $5,205,000 | 2.59% |
Iguana Healthcare Management, LLC | 75,000 | $3,945,000 | 2.25% |
Eventide Asset Management | 134,400 | $7,069,000 | 2.18% |
ASHFORD CAPITAL MANAGEMENT INC | 215,223 | $11,321,000 | 2.16% |